Melanoma Molecular Maps Projects


Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;

  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);

  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.

Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.

The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.


"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

Breslow thickness and 18F-FDG PET-CT result in initial staging of cutaneous melanoma: Can a cut-off point be established?
Ortega-Candil A, Rodríguez-Rey C, Cano-Carrizal R, Cala-Zuluaga E, González Larriba JL, Jiménez-Ballvé A, Fuentes-Ferrer ME, Cabrera-Martín MN, Pérez-Castejón MJ, García García-Esquinas M, Lapeña-Gutierrez L, Carreras-Delgado JL
Rev Esp Med Nucl Imagen Mol. 2015 Nov 17;():.
PMID: 26597332 [PubMed - as supplied by publisher]

Genetic Variants in the Vitamin D Pathway Genes VDBP and RXRA Modulate Cutaneous Melanoma Disease-Specific Survival.
Yin J, Liu H, Yi X, Wu W, Amos CI, Fang S, Lee JE, Han J, Wei Q
Pigment Cell Melanoma Res. 2015 Nov 17;():.
PMID: 26575331 [PubMed - as supplied by publisher]

Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.
Wheatley K, Wilson JS, Gaunt P, Marsden JR
Cancer Treat Rev. 2015 Nov 9;():.
PMID: 26563920 [PubMed - as supplied by publisher]

An analysis of the clinical trial landscape for cutaneous melanoma.
Perkins SH, Stensland KD, Galsky MD, Sivendran S
Cutis. 2015 Sep;96(3):186-90.
PMID: 26562269 [PubMed - in process]

Study of the histopathological types of cutaneous melanoma in Palmas-TO from 2001 to 2011.
Costa NF, Fernandes NC, Borges MR
An Bras Dermatol. 2015 Oct;90(5):638-45.
PMID: 26560208 [PubMed - in process]

NCBI's Disclaimer and Copyright notice